Episode Details

For our second entry of "Best of UEG Week 2024", Pradeep Mundre asks Iris Dotan to comment on her personal highlights in IBD in this year's UEG Week. Abstracts mentioned in the podcast & highlights:

• THE EFFICACY OF MAINTENANCE TREATMENT WITH GUSELKUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: PHASE 3 QUASAR MAINTENANCE STUDY RESULTS AT WEEK 44 BY BIOLOGIC/JANUS KINASE INHIBITOR HISTORY
• IMPACT OF GUSELKUMAB MAINTENANCE THERAPY ON HISTOLOGIC AND COMBINED HISTOLOGIC AND ENDOSCOPIC OUTCOMES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: WEEK 44 RESULTS FROM THE PHASE 3 QUASAR MAINTENANCE STUDY
• REAL-WORLD SHORT-TERM EFFECTIVENESS OF RISANKIZUMAB IN REFRACTORY CROHN’S DISEASE: RISANCROHN STUDY FROM THE ENEIDA REGISTRY
• EFFICACY AND SAFETY OF RO7790121, A FULLY HUMAN MONOCLONAL ANTIBODY BLOCKING TUMOUR NECROSIS FACTOR-LIKE LIGAND 1A IN MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING PHASE 2B TUSCANY-2 STUDY
• LONG-TERM EFFICACY AND SAFETY OF TULISOKIBART IN PATIENTS WITH CROHN’S DISEASE (CD): RESULTS FROM THE OPEN-LABEL EXTENSION PERIOD OF THE PHASE 2 APOLLO-CD STUDY
• NEED FOR A SECOND INTESTINAL RESECTION IN PATIENTS WITH CROHN’S DISEASE BEFORE AND AFTER ANTI-TNF AVAILABILITY. LONG-TERM DATA FROM THE ENEIDA REGISTRY
• THE ROLE OF SOMATIC MUTATIONS IN THE PATHOGENESIS OF INFLAMMATORY BOWEL DISEASE
• RISANKIZUMAB, BUT NOT USTEKINUMAB OR VEDOLIZUMAB, DOWNREGULATES IL-23-INDUCED MUCOSAL PATHOGENIC TH17 CELLS IN PATIENTS WITH CROHN’S DISEASE